Cybin Announces Major Clinical and Regulatory Milestones Alongside First Quarter Fiscal Year 2026 Financial Results Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN), a clinical-stage breakthrough neuropsychiatry company focused on…
Alto Neuroscience Appoints Raymond Sanchez, M.D., to Board of Directors, Strengthening Leadership as Company Advances Late-Stage Precision Psychiatry Pipeline Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company pioneering…
Innoviva Specialty Therapeutics Earns Dual Nominations for 2025 Prix Galien USA Best Pharmaceutical Product Award for ZEVTERA® and XACDURO® Innoviva Specialty Therapeutics, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ:…
Pilatus Biosciences Launches Clinical Trial Collaboration with Roche to Advance First-in-Human Evaluation of PLT012 in Liver Cancer Pilatus Biosciences, Inc., a biotechnology company focused on developing innovative metabolic checkpoint immunotherapies…
Infinity Bio Partners with Austrian Institute of Technology to Deliver Antibody Reactome Profiling Across Europe Infinity Bio, Inc., a pioneering leader in advanced immune system analysis, has announced a strategic…
Response Pharmaceuticals Announces Positive Phase 2 Results for RDX-002 in Post-GLP-1 Obesity Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation therapies for weight management and metabolic…
TriSalus Life Sciences Announces Strong Q2 2025 Results, Affirms Full-Year Outlook, and Advances Strategic Focus on Liver-Directed Therapies TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company pioneering innovative delivery…
Bionova Scientific® Inaugurates Advanced Plasmid DNA Production Facility in Texas to Support Surging Global Demand for Cell and Gene Therapy Materials Bionova Scientific®, a full-service biologics contract development and manufacturing…
Bayer and Kumquat Biosciences Forge Global Exclusive Agreement to Advance Next-Generation KRAS G12D Inhibitor in Precision Oncology Bayer AG, a global life sciences company with a growing presence in oncology,…
Newron Pharmaceuticals Launches Pivotal Phase III ENIGMA-TRS Program, Randomizing First Patients to Evaluate Evenamide as an Add-On Therapy in Treatment-Resistant Schizophrenia Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical…
PureTech Health Launches Celea Therapeutics to Transform the Treatment Landscape for Respiratory Diseases PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company committed to…
Pfizer and Astellas Announce Landmark Phase 3 Results for PADCEV™ Plus KEYTRUDA™ in Muscle-Invasive Bladder Cancer, Marking Potential Paradigm Shift in Treatment for Cisplatin-Ineligible Patients Pfizer Inc. (NYSE: PFE) and…